Fig. 3From: Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumabA 70-year-old female patient who received 6 ranibizumab injections in the year before baseline and 5 aflibercept injections in 1Â year of follow up. She showed good response to aflibercept with complete resolution of subretinal fluid at Month 3 that was maintained through Month 12. a Baseline, b Month 1, c Month 3, d Month 6, e Month 12Back to article page